Sandoz

Triple honors for Sandoz at last night’s Global Generics & Biosimilars Awards in Milan, where we won the night’s top award, Company of the Year, CEO Richard Saynor was named as Leader of the Year, and Sandoz also took the Biosimilars Initiative of the Year Award. Congratulations to Richard (who has now won this award for four of the past five years), to the biosimilars team behind our recent string of successful launches and approvals, and – most of all – to the 20,000-plus employees who all deserve individual medallions for the company award! The wins are testament to our common Purpose – pioneering access for patients – and we accept them in that spirit. Our congratulations to the other winners and our thanks to the Generics Bulletin team, who do a great job day in day out of pioneering access to essential news about our system-critical industry! See here for more details: https://lnkd.in/gj8Gm2wU Now it’s back to work! #GGBA #Biosimilars #Generics

Today, on #WorldSightDay, we recognize the millions of people worldwide who are impacted by blindness and vision impairment. There are many challenges stemming from vision loss and accessible treatment options are crucial to help patients maintain their sight and improve their quality of life. Join the #LoveYourEyes campaign along with advocates from around the world committed to prioritizing eye health including the International Agency for the Prevention of Blindness (IAPB). Learn more about the day here: https://lnkd.in/eNGA4Dz3 #Ophthalmology

At Sandoz, the wellbeing of our employees is critical, and a natural extension of our Purpose. This is why we have introduced support for our associates ranging from mindfulness to one-to-one counselling. Learn more: https://lnkd.in/gBpsA4Nf #Careers #SandozLife #WorldMentalHealthDay

Exactly one year ago, Sandoz celebrated becoming the ‘oldest’ new company listed on the SIX Swiss Exchange. The spin-off from our parent company marked the start of a new era for Sandoz, a brand that dates back to 1886. A lot has happened since we rang that initial cowbell 12 months ago (the traditional ‘entry ceremony’ for new joiners at the SIX in Zurich). Sandoz today has clearly established itself as the independent global leader in off-patent medicines, with steady sales growth backed up by a string of strategic achievements, from key acquisitions to product approvals and launches. Most importantly, we are investing significantly to drive future growth, both in the rapidly-accelerating biosimilar segment and in key areas of our core generics business. We have a broad and deep pipeline including an industry-leading 25 biosimilars and more than 450 generics. If you've taken one of our medicines in the last year, you're in good company: our medicines provide more than 800 million treatments every year. So thank you for your trust in Sandoz. Together, we'll continue to push the boundaries of what's possible in healthcare! #PioneeringAccess

Unsustainable pricing pressure and abusive patent litigation tactics are just a few factors that can cause market exits which contribute to drug shortages. For over 40 years, generic medicines have improved access for US patients, transforming health outcomes and driving down out-of-pocket costs for millions, but now urgent action is needed to be sure all patients can get the medicines they need, when they need them. Our goal is to ensure uninterrupted access to affordable medicines and make a difference for patients and the US healthcare system – but we cannot do it alone. Sandoz and the Association for Accessible Medicines urge the government to consider the unique aspects that differentiate the brand and generic business models and adopt policies that will reduce drug shortages by improving the long-term sustainability of the generic drug market. What happens next must happen now. Learn more about what Sandoz is doing at www.us.sandoz.com #PioneeringAccess

The passing of the Hatch-Waxman Act in 1984 helped the promise of generic medicines become a reality in the US. Now, forty years later, we sit on the brink of realizing the immense potential of biosimilars to reduce costs and increase access to high-priced biologic treatments in the US. It’s a pivotal moment – and one that is not without its challenges, including misaligned incentives across the US healthcare system that can inflate healthcare costs and restrict patient access to these more affordable alternatives. It’s crucial for stakeholders to advocate for policy changes that promote fair competition and prioritize patient welfare. It is only then that the full potential of biosimilars will be unlocked, ensuring a more sustainable and equitable healthcare system. What happens next must happen now. Learn more about what Sandoz is doing at www.us.sandoz.com #PioneeringAccess

Last week, Sandoz published its very own Generic Sustainability Report – a roadmap for policymakers on the critical changes needed to ensure continued patient access to generic medicines in the US. Have you had a chance to read the report? Share your thoughts in the comments below. Learn more here: https://bit.ly/3XUNW7q #genericmedicines #patientaccess

Without immediate action, we could face a reality where shortages of drugs for critical, acute, and chronic conditions, alike, are increasingly common – not to mention, the U.S. will leave billions of dollars in healthcare savings on the table. There is an urgent need to advance pragmatic solutions to mitigate these issues and support the sustainable implementation of generic medicines in service for patients today, and to ensure stronger healthcare systems of the future. We are committed to working together with stakeholders and policymakers to overcome existing barriers impacting the availability of generics, ensure reliability in manufacturing and consistent access to high-quality medicines for all patients, and supporting the long-term sustainability of our nation’s health care systems. But we cannot do it alone. What happens next must happen now. Learn more about what Sandoz is doing at www.US.sandoz.com #sandoz #PioneeringAccess

In today's dynamic and ever-evolving world, continuous learning and personal growth are key. #Sandoz is working to help colleagues like Camila Dias Gomes unlock their full potential and achieve their professional aspirations. As we collectively build the Sandoz of the future, we will continue to prioritize the personal and professional growth of all Sandoz colleagues. Learn more: https://lnkd.in/evdXGjtY #SandozLife #PersonalGrowth

Biosimilar medicines can help healthcare systems expand patient access to innovative biologics while generating vital cost savings. However, many critical biologics set to lose exclusivity currently do not have a biosimilar candidate in the pipeline. In an opinion piece with the European Pharmaceutical Review, our Global Head Biosimilars and Country President Austria, Peter Stenico, discusses the importance of addressing this 'biosimilar void'. Peter explains that by creating a favorable environment for biosimilars in Europe, we can attract more competition and help healthcare systems deliver on the rising demand for high-quality care while managing costs. To learn more, read Peter's article in full in EPR's latest Pharma Horizons report:  https://lnkd.in/eX-aqeJf #Sandoz #Biosimilars #PioneeringAccess